Results 61 to 70 of about 51,359 (234)

The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.

PLoS ONE, 2014
ObjectiveAlthough studies have shown an association between pioglitazone and bladder cancer, the associated factors have not been identified. The aim of this study was to investigate the factors that may link pioglitazone to bladder cancer.Materials and ...
Mei-Yueh Lee, Pi-Jung Hsiao, Yi-Hsin Yang, Kun-Der Lin, Shyi-Jang Shin   +4 more
doaj   +1 more source

The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer. [PDF]

, 2008
Decreased expression of peroxisome proliferator activated receptor-gamma (PPARgamma) and high levels of the proinflammatory enzyme cyclooxygenase-2 (COX-2) have been observed in many tumor types.
Dubinett, Steven M, Hazra, Saswati, Mao, Jenny T, Peebles, Katherine A, Sharma, Sherven   +4 more
core  

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis [PDF]

, 2010
Background Nonalcoholic steatohepatitis is a common liver disease that can progress to cirrhosis. Currently, there is no established treatment for this disease.
Bass, Nathan M., Brunt, Elizabeth M., Chalasani, Naga, Clark, Jeanne, Diehl, Anna Mae, Hoofnagle, Jay H., Kleiner, David E., Kowdley, Kris V., Lavine, Joel E., McCollough, Arthur, Neuschwander-Tetri, Brent A., Robuck, Patricia R., Sanyal, Arun J., Tonascia, James, Unalp, Aynur, Van Natta, Mark   +15 more
core   +2 more sources

Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once‐weekly dosing that supports adherence. However, injection‐site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause ...
Shifa Taj, Mohammed Zuber, Muhammed Rashid, Manik Chhabra, Krishna Undela, Smita Rawal, Lorenzo Villa Zapata   +6 more
wiley   +1 more source

Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis

Scientific Reports, 2017
Non-alcoholic fatty liver disease closely contributes to the development of obesity and insulin resistance. Even though pioglitazone has been reported to effectively lessen hepatic steatosis in human studies, its molecular mechanism remains unclear. This
Pi-Jung Hsiao, Hsin-Ying Clair Chiou, He-Jiun Jiang, Mei-Yueh Lee, Tusty-Jiuan Hsieh, Kung-Kai Kuo   +5 more
doaj   +1 more source

PPAR Gamma Receptor: A Novel Target to Improve Morbidity in Preterm Babies

Pharmaceuticals, 2023
Worldwide, three-quarters of a million babies are born extremely preterm (
Suresh Victor, Ben Forbes, Anne Greenough, A. David Edwards   +3 more
doaj   +1 more source

Treating hepatic steatosis and fibrosis by modulating mitochondrial pyruvate metabolism [PDF]

, 2019
A hepatic comorbidity of metabolic syndrome, known as nonalcoholic fatty liver disease (NAFLD), is increasing in prevalence in conjunction with the pandemics of obesity and diabetes.
Finck, Brian N, McCommis, Kyle S
core   +2 more sources

Cyclosorus terminans extract and pioglitazone equally alleviate metabolic disturbance and brain pathology in prediabetic rats [PDF]

, 2023
Wasana Pratchayasakul, Kenneth Chattipakorn, Natthaphat Siri‐Angkul, Jirachaya Choovuthayakorn, Thanapat Charumporn, Benjamin Ongnok, Napatsorn Saiyasit, Sornram Janjek, Busarin Arunsak, Titikorn Chunchai, Sujinda Songtrai, Sireewan Kaewsuwan, Nipon Chattipakorn, Siriporn C. Chattipakorn   +13 more
openalex   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

Effect of pioglitazone on proteinuria and cardiovascular events in patients with diabetic nephropathy [PDF]

, 2023
Seyyedeh Mina Hejazian, Sepideh Zununi Vahed, Nooshin Khadem Haghighi, Bahram Niknafs, Farahnoosh Farnood   +4 more
openalex   +1 more source